Buchumschlag

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial

Aims Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. Methods and results The interplay of RHR an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Böhm, Michael (VerfasserIn) , Butler, Javed (VerfasserIn) , Mahfoud, Felix (VerfasserIn) , Filippatos, Gerasimos (VerfasserIn) , Ferreira, João Pedro (VerfasserIn) , Pocock, Stuart J. (VerfasserIn) , Slawik, Jonathan (VerfasserIn) , Brückmann, Martina (VerfasserIn) , Linetzky, Bruno (VerfasserIn) , Schüler, Elke (VerfasserIn) , Wanner, Christoph (VerfasserIn) , Zannad, Faiez (VerfasserIn) , Packer, Milton (VerfasserIn) , Anker, Stefan D. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 4 October 2022
In: European journal of heart failure
Year: 2022, Jahrgang: 24, Heft: 10, Pages: 1883-1891
ISSN:1879-0844
DOI:10.1002/ejhf.2677
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ejhf.2677
Verlag, lizenzpflichtig, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2677
Volltext
Verfasserangaben:Michael Böhm, Javed Butler, Felix Mahfoud, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Jonathan Slawik, Martina Brueckmann, Bruno Linetzky, Elke Schüler, Christoph Wanner, Faiez Zannad, Milton Packer, and Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators
Beschreibung
Zusammenfassung:Aims Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. Methods and results The interplay of RHR and empagliflozin effects in EMPEROR-Preserved was evaluated. We grouped patients (n = 5988) according to their baseline RHR (<70 bpm [n = 2650], 70-75 bpm [n = 967], >75 bpm [n = 1736]) and explored the influence of RHR on CVD or HHF (primary outcome) and its components in sinus rhythm or atrial fibrillation/flutter (AF) and adverse events. We studied the efficacy of empagliflozin across the RHR spectrum. Compared to placebo, empagliflozin did not change heart rate over time. The primary outcome (p for trend = 0.0004) and its components CVD (p trend = 0.0002), first HHF (p for trend = 0.0099) and all-cause death (p < 0.0001) increased with RHR only in sinus rhythm but not AF. The risk increase with RHR was similar in patients with heart failure and mildly reduced ejection fraction (left ventricular ejection fraction [LVEF] 40-49%) and HFpEF (LVEF ≥50%). Baseline RHR had no influence on the effect of empagliflozin on the primary outcomes (p for trend = 0.20), first HHF (p for trend = 0.49). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the RHR groups. Conclusion Resting heart rate associates with outcomes only in sinus rhythm but not in AF. Empagliflozin reduced outcomes over the entire RHR spectrum without increase of adverse events.
Beschreibung:Gesehen am 01.08.2023
Beschreibung:Online Resource
ISSN:1879-0844
DOI:10.1002/ejhf.2677

Ähnliche Einträge